scholarly journals Locally Advanced Cervical Carcinoma Management

2018 ◽  
Author(s):  
Achille Manirakiza ◽  
Sumi Sinha ◽  
Fidel Rubagumya
Keyword(s):  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

Enhanced Radiosensitization with Interferon-α-2b and Cisplatin in the Treatment of Locally Advanced Cervical Carcinoma

1997 ◽  
Vol 67 (3) ◽  
pp. 309-315 ◽  
Author(s):  
Richard G. Stock ◽  
Peter Dottino ◽  
T.Scott Jennings ◽  
Mitchell Terk ◽  
J.Keith Dewyngaert ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Interferon Α ◽  
Advanced Cervical Carcinoma

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

1995 ◽  
Vol 109 (8) ◽  
pp. 744-747 ◽  
Author(s):  
John S. Rubin ◽  
Scott Wadler ◽  
Jonathan J. Baitler ◽  
Hilda Haynes ◽  
Alla Rozenblet ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Hearing Threshold ◽  
High Dose ◽  
High Frequencies ◽  
Advanced Cervical Carcinoma ◽  
Before And After ◽  
Audiologic Testing

AbstractWR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

180 Combined radiotherapy with irinotecan (CPT-11), interferon a2b (IFNa2b) and amifostine in patients with locally advanced cervical carcinoma (LACC)

2003 ◽  
Vol 1 (5) ◽  
pp. S57
Author(s):  
G. Sarris ◽  
D. Bafaloukos ◽  
N. Koliarakis ◽  
Th. Akrivos ◽  
H. Athanassiou ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort

2018 ◽  
Vol 151 (2) ◽  
pp. 215-220 ◽  
Author(s):  
Hannah M. Simonds ◽  
Matthys H. Botha ◽  
Alfred I. Neugut ◽  
Frederick H. Van Der Merwe ◽  
Judith S. Jacobson
Keyword(s):  
Overall Survival ◽  
South African ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Hiv Positive ◽  
Advanced Cervical Carcinoma ◽  
Hiv Negative

scholarly journals Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma

Medicine ◽  
2020 ◽  
Vol 99 (1) ◽  
pp. e18663
Author(s):  
Jiahao Zhu ◽  
Zheng Zhang ◽  
Dongyan Bian ◽  
Qingqing Chen ◽  
Qunchao Hu ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

Our Experience of Laparoscopic Anterior Exenteration in Locally Advanced Cervical Carcinoma

2016 ◽  
Vol 23 (3) ◽  
pp. 396-403 ◽  
Author(s):  
Shailesh Puntambekar ◽  
Vikrant Sharma ◽  
Arun V. Jamkar ◽  
Yamini Gadkari ◽  
Geetanjali Joshi ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Advanced Cervical Carcinoma

scholarly journals Concurrent chemoradiation in treatment of carcinoma cervix

1970 ◽  
Vol 2 (1) ◽  
pp. 4-8
Author(s):  
Meeta Singh ◽  
Rajshree Jha ◽  
Josie Baral ◽  
Suniti Rawal
Keyword(s):  
Cervical Cancer ◽  
Radiation Therapy ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Concurrent Chemoradiation ◽  
Advanced Cervical Cancer ◽  
European Organization ◽  
Locally Advanced Cervical Cancer ◽  
Advanced Cervical Carcinoma ◽  
To Come

Aim: to compare if concurrent chemoradiation is better than radiotherapy given alone in the treatment of women with locally advanced cervical cancer from published literature Method: Study Design: Randomized control trials of > than 2, 403 women participants who underwent treatment for advanced cervical carcinoma mainly in two huge center i.e. from National Cancer Institute (NCI), USA and European Organization for Research and Treatment of Cancer (EORTC) were reviewed regarding the treatment they received at the center: concurrent chemoradiation/ radiation therapy alone. The results were analyzed to come to conclusion. Result demonstrated a 30-50% improvement in survival when cisplatin-based chemotherapy in NCI or 5 fluorouracil and cisplatin based chemotherapy was used in EORTC was administered with concurrent radiation therapy (chemoradiation) Conclusions: The addition of chemotherapy (cisplatin) in NCI and (cisplatin and fluorouracil) in the EORTC for the treatment of locally advanced cervical cancer with the concurrent chemoradition have elicited better survival than those treated with radiotherapy alone dittoed by several other trials which can be anticipated to benefit Nepalese women with locally advanced cervical carcinoma. Key-words: Cancer cervix, chemoradiation, radiotherapy   doi:10.3126/njog.v2i1.1467 N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4 - 8 May -June 2007

Sign in / Sign up

Export Citation Format

Share Document